SOVALDI (sofosbuvir) by Gilead Sciences is rna replicase inhibitors [moa]. Approved for hepatitis c virus nucleotide analog ns5b polymerase inhibitor [epc]. First approved in 2019.
Drug data last refreshed Yesterday
RNA Replicase Inhibitors
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
Worked on SOVALDI at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo